Showing 2751-2760 of 9152 results for "".
Where Does Phototherapy Still Fit In?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/where-does-phototherapy-still-fit-in/48783/Christopher Bunick, MD, FAAD, discusses the situations in which phototherapy can still be useful in the age of advanced systemic therapies.SCALE 2024: Dr. Hilary Baldwin on Benzyl Peroxide Best Practices
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwin-benzyl-peroxide-best-practices/26375/Hilary E. Baldwin, MD, provides and update on the recent issues surrounding benzyl peroxide, including a recommendation to dispose of any expired benzyl peroxide products and a discussion of proper storage, at Music City SCALE.Trends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.First, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.Scientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoTolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pDermWireTV: Sun Hero Launch; Eczema Awareness Month; ASDSA Hails Hyaluron Pen Warning
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-sun-hero-launch-eczema-awareness-month-asdsa-hails-hyaluron-pen-warning/20006/An estimated 80% of skin damage occurs before age 18. L'Oreal brands CeraVe and LaRoche-Posay have teamed with Dr. Amy Brodsky to launch the Sun Hero campaign to educate young people about UV safety. Throughout Eczema Awareness month, the National Eczema Association is spotlighting aspects of the diAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anThe Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.